Vaxcyte advances VAX-31 as Phase 3 trial design choices highlight regulatory and adoption priorities
Vaxcyte advances VAX-31 into pivotal adult and infant studies. Find out how trial design choices shape regulatory and adoption outcomes.
Pharma & Biotech
Features & Analysis
How Sanofi’s CpG 1018 platform could reshape vaccine formulation in 2026
Sanofi's acquisition of CpG 1018 brings TLR9 adjuvants to the forefront. Explore how this could transform combo vaccines and adult immunization strategies.
Pharma & Biotech
Why Sanofi’s $2.2bn Dynavax deal is a high-stakes bet on adult vaccines
Sanofi to acquire Dynavax for $2.2B to boost adult vaccines. Find out how HEPLISAV-B and Z-1018 fit into Sanofi’s global immunization strategy.